CRISPR Therapeutics AG: ARK Investment Management LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
ARK Investment Management LLC amended its Schedule 13G filing for CRISPR Therapeutics AG, disclosing a change in its passive stake in the gene-editing company. The filing, submitted under SEC accession number 0001104659-26-126825, updates ARK's previously reported beneficial ownership position. The amendment signals a shift in the size of ARK's holding, though the filing summary did not specify the exact percentage change. Investors watch 13G amendments for signals about how major institutional holders are positioning in volatile biotech names. Next, watch for further ARK disclosures and CRISPR Therapeutics' upcoming financial results for confirmation of the fund's stance.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
ARK Investment Management LLC, CRISPR Therapeutics AG